Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Eur J Pain. 2016 Sep 15;21(3):456–465. doi: 10.1002/ejp.939

Figure 4.

Figure 4

The sEHI effectively mediates analgesia in neuropathic pain and outperforms celecoxib. (a) When the sEHI TPPU at 10mg/kg was tested in naïve mice it had no significant effect in the CPP assay. The same 10mg/kg dose of celecoxib seemed to induce a response but it was not significant (One Way ANOVA, p=0.132). In the CPP assay this is indicated by increased time (seconds, y axis) spent in the drug paired chamber. (b) When assessed in diabetic neuropathic mice the 10mg/kg TPPU showed a significant and robust response and celecoxib was without effect (One Way ANOVA, p=0.003). The diabetic mice were assessed for phenotypic allodynia indicating diabetic neuropathy in the von Frey assay. The results depicted below the graph (where applicable) are the grams of force to elicit a hind paw withdrawal (von Frey (gr)) of pre-streptozocin baseline scores (Naïve) and post streptozocin painful baseline scores (Diabetic) prior to the start of treatment in the CPP assay.